Agenda:
- 12pm-1pm Lunch
- 1pm-2pm When to optimise therapy
- 2.15pm-3.15pm Practicalities of starting GLP 1 receptor agonist therapy
- 3.30pm-4.30pm Understanding GLP-1 Ra’s
- 4.30pm Q&A
- 5pm Close
When to optimise therapy
- To understand the underlying pathophysiology that leads to hyperglycaemia in T2DM
- To discuss the concept of clinical inertia
- To apply the guidelines from theory into practice
- To understand the considerations for developing individualised care
- Choosing GLP 1 Receptor agonists
- To understand how the physiological benefits of native GLP 1 have been translated into the therapeutic class of GLP 1 RAs
- To examine existing guidelines and their application to practice
- To explore the impact of cardiovascular data on evolving guidance
- To explore differences between the GLP 1 Receptor Agonists with a human GLP 1 backbone
- To use case studies to illustrate key points
Practicalities of starting GLP 1 receptor agonist therapy
- To understand how a thorough assessment of the patient’s baseline parameters can support implementation of GLP 1 RA therapy
- To develop an awareness of the various GLP 1 RA devices and methods of administration
- To understand the process involved in the initiation of GLP 1 RA therapy, including special considerations
- To determine necessary factors for ongoing management
Understanding GLP 1 Receptor agonists
- To understand the incretin effect
- To understand the effects of GLP 1 in humans
- To understand the effects of GLP 1 receptor agonists in type 2 diabetes
- To explore ways to ensure timely initiation of GLP 1 receptor agonists
Your contact details will be shared with Lilly.
Speakers:
Professor Vinod Patel
FHEA FRCP MD MRCGP DRCOG PSc. Professor, Diabetes and Clinical Skills, Hon Consultant in Endocrinology and Diabetes
Louise Dodd, RGN, MSc, INP
Nicky Suddick, Community Diabetes Specialist Nurse, Coventry, Rugby and Warwickshire